Observational studyEuropean journal of pediatrics2026
Performance of a host-protein score (MeMed BV score) for detecting bacterial infections in young children.
Observational study in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosing bacterial infections in children with fever without source remains challenging. The MeMed BV score, combining C-reactive protein, interferon gamma-induced protein-10, and tumor necrosis factor-related apoptosis-inducing ligand, has shown high performance in detecting bacterial infections, mostly in adults. The objective of this study is to explore the diagnostic performance of the MeMed BV score in identifying bacterial infections in young children with fever without source. In this prospective exploratory observational study, children younger than 3 years presenting to the pediatric emergency departments with acute fever without source were eligible for inclusion. An adjudication committee reviewed clinical and microbiological data to establish the diagnosis of bacterial infection. The MeMed BV score ranged from 0 to 100, with manufacturer-validated thresholds: < 35 viral, > 65 bacterial, 35-65 equivocal. In the main analysis, equivocal scores were considered bacterial. A sensitivity analysis was subsequently performed excluding patients with equivocal scores. The performance of MeMed BV score was compared to procalcitonin. Among the 384 eligible children, 69 were analyzed. Median age was 2 months (IQR 1-10), and 25% had a bacterial infection. The sensitivity of MeMed BV was 47.1% (95% CI 23.0-72.2), the specificity was 84.6% (95% CI 72.1-93.1), and the area under the curve was 0.80 (95% CI 0.69-0.92). Procalcitonin's sensitivity was 82.4% (95% CI 56.6-96.2).
conclusionIn infants under 3 years old with fever without source, the MeMed BV showed limited sensitivity and warrants further evaluation before routine clinical implementation. WHAT IS KNOWN: • The MeMed BV score, a diagnostic test combining three proteins, has shown good performance in adults for detecting bacterial infections. • Children under 3 years of age are particularly at risk of bacterial infections, making early diagnosis crucial. WHAT IS NEW: • In this study, MeMed BV showed low sensitivity (47.1%), missing several bacterial infections. • These findings suggest that MeMed BV should be interpreted with caution when used to identify bacterial infections in young children presenting with fever without a source.
Indexed as
Identifiers
42622693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.